Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Research from Oregon Health & Science University, Department of Surgery provides new data about adenocarcinoma
April 13th, 2008
A report, 'The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging,' is newly published data in Journal of Gastrointestinal Surgery. According to a study from the United States, "Although neoadjuvant chemoradiation eradicates esophageal adenocarcinoma in a substantial proportion of patients, conventional imaging techniques cannot accurately detect this response. Dynamic contrast-enhanced magnetic resonance imaging is an emerging approach that may be well suited to fill this role." "This pilot study evaluates the ability of this method to discriminate adenocarcinoma from normal esophageal tissue. Patients with...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-13)
|
